Is there a role for continuation of CDK4/6 inhibition after progression on a prior CDK4/6 inhibitor in HR+/HER2- metastatic breast cancer?

Giordano, A; Lin, N U; Tolaney, S M; Mayer, E L

Giordano, A; Lin, N U; Tolaney, S M; Mayer, E L.

Afiliação

Giordano A; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
Lin NU; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
Tolaney SM; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.
Mayer EL; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA. Electronic address: erica_mayer@dfci.harvard.edu.

Ann Oncol ; 35(1): 10-14, 2024 Jan.

Article em En | MEDLINE | ID: mdl-37952893

Assuntos

Neoplasias da Mama; Humanos; Feminino; Neoplasias da Mama/tratamento farmacológico; Estudos Longitudinais; Quinase 4 Dependente de Ciclina; Receptor ErbB-2; Inibidores de Proteínas Quinases/farmacologia; Inibidores de Proteínas Quinases/uso terapêutico; Protocolos de Quimioterapia Combinada Antineoplásica

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Idioma: En Ano de publicação: 2024 Tipo de documento: Article